Safety and tolerability of high-dose formoterol (Aerolizer) and salbutamol (pMDI) in patients with mild/moderate, persistent asthma

This double-blind, double-dummy, crossover study evaluated the tolerability of high-dose formoterol and salbutamol. Sixteen adults with mild/moderate persistent asthma (FEV 1≥70% predicted) were randomized to receive either formoterol 36 μg three times daily (TID) at 5-h intervals via Aerolizer ® (t...

Full description

Saved in:
Bibliographic Details
Published in:Pulmonary pharmacology & therapeutics 2005-01, Vol.18 (3), p.229-234
Main Authors: Kruse, Matthias, Rosenkranz, Bernd, Dobson, Clair, Ayre, Gareth, Horowitz, Ann
Format: Article
Language:English
Subjects:
Adult
Aerolizer
Aerosols
Albuterol - administration & dosage
Albuterol - adverse effects
Albuterol - therapeutic use
Asthma
Asthma - drug therapy
Blood Pressure - drug effects
Bronchodilator Agents - administration & dosage
Bronchodilator Agents - adverse effects
Bronchodilator Agents - therapeutic use
Cross-Over Studies
Double-Blind Method
Drug Administration Schedule
Electrocardiography
Ethanolamines - administration & dosage
Ethanolamines - adverse effects
Ethanolamines - therapeutic use
Female
Forced Expiratory Volume - drug effects
Formoterol
Formoterol Fumarate
Humans
Male
Middle Aged
Safety
Salbutamol
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This double-blind, double-dummy, crossover study evaluated the tolerability of high-dose formoterol and salbutamol. Sixteen adults with mild/moderate persistent asthma (FEV 1≥70% predicted) were randomized to receive either formoterol 36 μg three times daily (TID) at 5-h intervals via Aerolizer ® (total daily dose 108 μg), or salbutamol 600 μg TID via pressurized metered-dose inhaler (total daily dose 1800 μg) for 3 consecutive days. After a 3–7-day washout period patients received the other treatment. FEV 1 was measured 15 min pre-dose and 2 h post-dose. Both formoterol and salbutamol were associated with decreased plasma potassium (mean of minimum values: 3.4 and 3.6 mmol/L, respectively; P
ISSN:1094-5539
1522-9629
DOI:10.1016/j.pupt.2004.12.011